Flu shots have long been injected deep into muscle, requiring a needle an inch long or longer. Both Pfizer and Moderna have announced promising results from vaccine trials to battle COVID-19 | Jacquelyn Martin, Associated Press
A look at the differences between the vaccines Pfizer and Moderna are producing and what it means for you
Amid soaring case counts and increasingly crunched hospital systems, a spot of good news emerged Monday morning as Moderna announced its mRNA vaccine shows a 94.5% efficacy rate.
Moderna is the second company to share promising results from a phase 3 trial — a large scale assessment of vaccine safety and efficacy — that showed a two-dose vaccine was effective at preventing COVID-19.
Its data showed that two weeks after the second vaccine shot, 95 people in the study group had contracted COVID-19 — 90 who had received a placebo and 5 who’d gotten the vaccine. Of the 95 COVID-19 cases, 11 cases were severe, and all were placebo recipients.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Moderna’s CEO, Stéphane Bancel, said Monday morning in a release.
The company said it will ask for FDA emergency use authorization “in the …read more
Source:: Deseret News – Top stories